Melanie Grant
Research
Publications
-
Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products.
J Transl Med Volume: 23 Page(s): 259
03/04/2025 Authors: Simon CG; Bozenhardt EH; Celluzzi CM; Dobnik D; Grant ML; Lakshmipathy U; Nebel T; Peltier L; Ratcliffe A; Sherley JL -
Mechanism of action, potency and efficacy: considerations for cell therapies.
J Transl Med Volume: 22 Page(s): 416
05/02/2024 Authors: Simon CG; Bozenhardt EH; Celluzzi CM; Dobnik D; Grant ML; Lakshmipathy U; Nebel T; Peltier L; Ratcliffe A; Sherley JL -
MULTI-TUMOR ASSOCIATED ANTIGEN SPECIFIC T CELL (TAA-T) THERAPY TO TREAT PEDIATRIC PATIENTS WITH HIGH-RISK CNS TUMORS: THE REMIND TRIAL
Volume: 25 Page(s): S33 - S33
06/01/2023 Authors: Geiger A; Diccocio R; Fortiz M; Grant M; Lang H; Shibli A; Datar A; Reynolds E; Lazarski C; Jensen-Wachspress M -
OUTCOMES OF PEDIATRIC PATIENTS WITH HIGH-RISK CNS TUMORS TREATED WITH MULTI-TUMOR ASSOCIATED ANTIGEN SPECIFIC T CELL (TAA-T) THERAPY: THE REMIND TRIAL
Volume: 24 Page(s): 85 - 86
06/01/2022 Authors: Hwang E; Fortiz F; Cruz R; Geiger A; Grant M; Lang H; Shibli A; Burnett S; Lazarski C; Tanna J -
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
Blood Adv Volume: 6 Page(s): 2520 - 2534
04/26/2022 Authors: Kinoshita H; Cooke KR; Grant M; Stanojevic M; Cruz CR; Keller M; Fortiz MF; Hoq F; Lang H; Barrett AJ -
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Blood Adv Volume: 6 Page(s): 473 - 485
01/25/2022 Authors: Dave H; Terpilowski M; Mai M; Toner K; Grant M; Stanojevic M; Lazarski C; Shibli A; Bien SA; Maglo P -
Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.
Front Immunol Volume: 13 Page(s): 999298
01/01/2022 Authors: Stanojevic M; Grant M; Vesely SK; Knoblach S; Kanakry CG; Nazarian J; Panditharatna E; Panchapakesan K; Gress RE; Holter-Chakrabarty J -
Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
Nat Commun Volume: 12 Page(s): 6689
11/18/2021 Authors: Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR -
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
Cytotherapy Volume: 23 Page(s): 694 - 703
08/01/2021 Authors: Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee P-H; Lang H; Cruz CRY -
THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS
Volume: 23 Page(s): 52 - 52
06/01/2021 Authors: Grant M; Fortiz M; Wang L; Lang H; Datar A; Reynolds E; Terpilowski M; Geiger A; Lazarski C; Tanna J